Mar 06, 2026 (MarketLine via COMTEX) --
Shuttle Pharmaceuticals Holdings, Inc. said it entered into a securities purchase agreement to sell 2,238,800 shares and pre-funded warrants to purchase 4,761,200 shares in a public offering to raise approximately $3.5 million before fees.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock, in a public offering, for aggregate gross proceeds of approximately $3,500,000, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions.
E.F. Hutton & Co. is acting as the exclusive placement agent for the offering. The Company intends to use up to $1.5 million of the net proceeds from this offering for future marketing efforts and the remainder for working capital and general corporate purposes.
The securities described above are being offered and sold by the Company in a public offering pursuant to a registration statement on Form S-1 (File No. 333-293363) that was originally filed with the Securities and Exchange Commission (the "SEC") on February 11, 2026, and became effective on February 17, 2026. The offering of the securities is being made only by means of a prospectus that forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. A final prospectus relating to, and describing the terms of, the public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus relating to the public offering, when available, may also be obtained by contacting E.F. Hutton & Co., at 745 Fifth Avenue, 34th Floor & PH, New York, NY 10151, by telephone at v, or by email at info@efhutton.com.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_478976146/2227/2026-05-12T03:02:21
Copyright (C) 2026 Datamonitor. All rights reserved
